XML 11 R2.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 27,653 $ 59,074
Receivables from collaboration 144 23
Deferred product costs from collaboration 13,539 13,539
Prepaid expenses and other current assets 2,807 4,018
Total current assets 44,143 76,654
Property and equipment - net 48,033 48,749
Other assets 1,096 1,009
Total 93,272 126,412
Current liabilities:    
Accounts payable 582 15,599
Accrued expenses and other current liabilities 8,077 7,929
Facility financing obligation 75,010 74,582
Deferred product sales from collaboration 17,680 17,503
Deferred payments from collaboration 134,935 140,231
Purchase commitment liabilities - current 12,927 12,475
Total current liabilities 249,211 268,319
Note payable to principal stockholder 49,521 49,521
Sanofi loan facility and loss share obligation 68,835 62,371
Senior convertible notes 27,618 27,613
Net purchase commitments 55,605 53,692
Other liabilities 15,946 15,225
Total liabilities $ 466,736 $ 476,741
Commitments and contingencies
Stockholders' equity (deficit):    
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2016 and December 31, 2015
Common stock, $0.01 par value - 550,000,000 shares authorized at March 31, 2016 and December 31, 2015; 429,138,685 and 428,670,943 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively $ 4,290 $ 4,287
Additional paid-in capital 2,510,367 2,508,633
Accumulated other comprehensive loss (19) (20)
Accumulated deficit (2,888,102) (2,863,229)
Total stockholders' deficit (373,464) (350,329)
Total $ 93,272 $ 126,412